FindTrial
Sign In

Bypassing Agents

DRUG4 trials

Sponsors

Hoffmann-La Roche, Genzyme, a Sanofi Company, Tribhuvan University Teaching Hospital, Institute Of Medicine.

Conditions

Cardiac SurgeryCardiac Surgery Requiring Cardiopulmonary BypassHemophilia AHemophilia BVon Willebrand Disease, Type 3

Phase 3

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
CompletedNCT03417102
Genzyme, a Sanofi CompanyHemophilia A, Hemophilia B
Start: 2018-02-14End: 2021-06-23Updated: 2022-03-28
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
RecruitingNCT06998524
Hoffmann-La RocheVon Willebrand Disease, Type 3
Start: 2025-06-27End: 2029-04-30Target: 75Updated: 2026-09-09

Unknown Phase

A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment
CompletedNCT02476942
Hoffmann-La RocheHemophilia A
Start: 2015-05-26End: 2017-03-31Updated: 2017-05-30
Clinical Outcomes Between Pulsatile and Non-Pulsatile Flow During Cardiopulmonary Bypass
CompletedNCT07009730
Tribhuvan University Teaching Hospital, Institute Of Medicine.Cardiac Surgery, Cardiac Surgery Requiring Cardiopulmonary Bypass
Start: 2019-07-23End: 2020-07-23Updated: 2025-06-08

Related Papers

Experience with minor surgeries in people with hemophilia A or B with and without inhibitors receiving fitusiran
Blood2025-11-03
Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
Blood2025-03-0720 citations
Mechanistic Modeling to Support Hemostatic Equivalency of Antithrombin Lowering in People with Hemophilia A or B
Blood2024-11-05
Reduced Doses of Factor Concentrates and Bypassing Agents to Treat Breakthrough Bleeds in Patients with Hemophilia A and B on Fitusiran Antithrombin-Based Dosing Regimen: ATLAS-OLE
Blood2024-11-05
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial
Blood2024-03-0733 citations
Fitusiran Population Pharmacokinetic and Pharmacodynamic Modeling Utilizing Phase 3 Clinical Trial Data to Confirm Doses Tested in Phase 3 Trials to Support an Antithrombin-Based Dose Regimen
Blood2023-11-02
S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX
HemaSphere2023-08-01
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial.
2023-03-2977 citations
Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI)
Blood2021-11-0515 citations
Health‐related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors—A non‐interventional study
Haemophilia2021-02-1233 citations
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
Thrombosis and Haemostasis2020-10-2190 citations
Health‐related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study
Haemophilia2020-10-2133 citations
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study
Pediatric Blood & Cancer2020-08-0917 citations
Health‐related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non‐interventional study (NIS)
Haemophilia2019-04-2446 citations
Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non‐interventional study in a real‐world setting
Haemophilia2019-02-0638 citations
Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study
Blood2018-11-2937 citations
Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study
Blood2018-11-291 citations
Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi‐centre, non‐interventional study
Haemophilia2018-10-0831 citations
HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors
Blood2017-12-0753 citations
Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting
Blood2017-12-074 citations

1 more papers not shown